ENLV
Enlivex Therapeutics Ltd.
$0.90
-$0.02(-1.72%)
20
Overall
--
Value
20
Tech
--
Quality
Market Cap
$23.33M
Volume
220.13K
52W Range
$0.84 - $2.10
Target Price
$10.00
Company Overview
| Mkt Cap | $23.33M | Price | $0.90 |
| Volume | 220.13K | Change | -1.72% |
| P/E Ratio | -0.8 | Open | $0.91 |
| Revenue | -- | Prev Close | $0.91 |
| Net Income | $-29.1M | 52W Range | $0.84 - $2.10 |
| Div Yield | N/A | Target | $10.00 |
| Overall | 20 | Value | -- |
| Quality | -- | Technical | 20 |
No chart data available
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
Enlivex Therapeutics Advances Psoriatic Arthritis Treatment with Allocetra Study
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENLV | $0.90 | -1.7% | 220.13K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enlivex Therapeutics Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW